TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05887063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Awareness Course UK
Description: An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
Study: NCT04817189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, 8 mg (oral) or equivalent IV dose
Description: Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
Study: NCT06479239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR FPBMC
Description: Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.
Study: NCT06095037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful yoga
Description: 12 week mindful yoga intervention
Study: NCT06555159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)
Description: Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Continuous aerobic physical exercise
Description: Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
Study: NCT06095037

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: 12 week psychoeducation sessions
Study: NCT05024344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Study: NCT06185452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration
Description: Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration
Description: Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
Study: NCT04841590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of the experimental group (EG)
Description: Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
Study: NCT05796505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADVANCE Steering Committee interventions
Description: Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
Study: NCT04841590

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group (CG)
Description: Subjects in the control group (CG) will not receive any treatment
Study: NCT04801576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flouride in mouthrinses
Description: Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthrinse
Description: Mouthrinses without flouride
Study: NCT06357260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin and Carbamazepine
Description: Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
Study: NCT05334238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
Study: NCT05754424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT278
Description: Concentrated rapid acting insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT278
Description: Concentrated rapid acting insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid
Description: Rapid-acting insulin aspart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid
Description: Rapid-acting insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R 500 UNT/ML Injectable Solution
Description: Regular human insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin R 500 UNT/ML Injectable Solution
Description: Regular human insulin
Study: NCT06468423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX)
Description: Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO)
Description: DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
Study: NCT05570435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
Study: NCT06300489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposomes+capecitabine
Description: Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD).
Study: NCT04906278

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley catheter balloon
Description: A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley catheter balloon
Description: A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Amniotomy
Description: Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
Study: NCT05354089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 μg dose of SYS6006
Description: 20 μg dose of SYS6006 vaccine IM on day 0 and day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg dose of SYS6006
Description: 30 μg dose of SYS6006 vaccine IM on day 0 and day 21.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IM on day 0 and day 21.
Study: NCT06053762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-facilitated tobacco cessation
Description: Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-navigated tobacco cessation
Description: Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
Study: NCT05690074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Wave Writer™ Spinal Cord Stimulator System
Description: Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
Study: NCT05685277

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg
Description: Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg
Description: Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.

Intervention type: DRUG
Group type: OTHER
Intervention: Tritace® Plus tablet 10 mg/25 mg
Description: Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.

Intervention type: DRUG
Group type: OTHER
Intervention: Tritace® Plus tablet 10 mg/25 mg
Description: Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
Study: NCT05118516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC43F
Description: One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
Study: NCT06277115

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
Study: NCT06405633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucelotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucelotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucelotide
Study: NCT06389123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Study: NCT05378802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different modes of mechanical ventilation
Description: Four different ventilation modes were performed one by one and respiratory parameters were recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different modes of mechanical ventilation
Description: Four different ventilation modes were performed one by one and respiratory parameters were recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different modes of mechanical ventilation
Description: Four different ventilation modes were performed one by one and respiratory parameters were recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different modes of mechanical ventilation
Description: Four different ventilation modes were performed one by one and respiratory parameters were recorded.
Study: NCT04956679

Intervention type: DIAGNOSTIC_TEST
Intervention: carbon 13 breath test
Description: Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
Study: NCT05488366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
Study: NCT05698069

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Modulation Index
Description: A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.

Intervention type: OTHER
Intervention: Pain Detect
Description: A questionnaire that was validated for the assessment of neuropathic pain

Intervention type: OTHER
Intervention: Central sensitization inventory
Description: A questionnaire developed for the detection of central sensitization.
Study: NCT05816486

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunobiogram
Description: This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunobiogram
Description: This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunobiogram
Description: This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
Study: NCT04719377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter placement
Description: catheter placement

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: catheter placement
Description: catheter placement
Study: NCT05074836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula milk
Description: Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular milk
Description: Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months

Intervention type: OTHER
Group type: OTHER
Intervention: Control foods
Description: Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months
Study: NCT05148897

Intervention type: OTHER
Intervention: Questionnaire
Description: a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
Study: NCT05931744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline intrapolyp injection
Study: NCT04614675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal soft tissue procedure with TALR
Description: TALR group: Transarticular lateral release as the distal soft tissue procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal soft tissue procedure with PCLR
Description: PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
Study: NCT05640674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Non-opioid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Non-opioid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Description: Opioid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Non-opioid
Study: NCT06498752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody consolidation therapy
Description: PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
Study: NCT05328856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hansgrohe prototype
Description: Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out with a mixing function for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
Study: NCT06027931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative Access Opening, Traditional Access Opening
Description: Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative Access Opening, Traditional Access Opening
Description: Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.